Respiratory Research (Oct 2022)

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC

  • Eva M. Becker-Pelster,
  • Michael G. Hahn,
  • Martina Delbeck,
  • Lisa Dietz,
  • Jörg Hüser,
  • Johannes Kopf,
  • Thomas Kraemer,
  • Tobias Marquardt,
  • Thomas Mondritzki,
  • Johannes Nagelschmitz,
  • Sylvia M. Nikkho,
  • Philippe V. Pires,
  • Hanna Tinel,
  • Gerrit Weimann,
  • Frank Wunder,
  • Peter Sandner,
  • Joachim Schuhmacher,
  • Johannes-Peter Stasch,
  • Hubert K. F. Truebel

DOI
https://doi.org/10.1186/s12931-022-02189-1
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Background Oxidative stress associated with severe cardiopulmonary diseases leads to impairment in the nitric oxide/soluble guanylate cyclase signaling pathway, shifting native soluble guanylate cyclase toward heme-free apo-soluble guanylate cyclase. Here we describe a new inhaled soluble guanylate cyclase activator to target apo-soluble guanylate cyclase and outline its therapeutic potential. Methods We aimed to generate a novel soluble guanylate cyclase activator, specifically designed for local inhaled application in the lung. We report the discovery and in vitro and in vivo characterization of the soluble guanylate cyclase activator mosliciguat (BAY 1237592). Results Mosliciguat specifically activates apo-soluble guanylate cyclase leading to improved cardiopulmonary circulation. Lung-selective effects, e.g., reduced pulmonary artery pressure without reduced systemic artery pressure, were seen after inhaled but not after intravenous administration in a thromboxane-induced pulmonary hypertension minipig model. These effects were observed over a broad dose range with a long duration of action and were further enhanced under experimental oxidative stress conditions. In a unilateral broncho-occlusion minipig model, inhaled mosliciguat decreased pulmonary arterial pressure without ventilation/perfusion mismatch. With respect to airway resistance, mosliciguat showed additional beneficial bronchodilatory effects in an acetylcholine-induced rat model. Conclusion Inhaled mosliciguat may overcome treatment limitations in patients with pulmonary hypertension by improving pulmonary circulation and airway resistance without systemic exposure or ventilation/perfusion mismatch. Mosliciguat has the potential to become a new therapeutic paradigm, exhibiting a unique mode of action and route of application, and is currently under clinical development in phase Ib for pulmonary hypertension.

Keywords